argenx (ARGX) Stock Forecast, Price & News

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for argenx in the last year. There are currently 1 hold rating and 18 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ARGX shares.
View ARGX analyst ratings or view top-rated stocks.

19 Wall Street analysts have issued 12 month price targets for argenx's shares. Their ARGX share price forecasts range from $425.00 to $494.00. On average, they anticipate the company's stock price to reach $455.67 in the next year. This suggests a possible upside of 17.1% from the stock's current price.
View analysts price targets for ARGX or view top-rated stocks among Wall Street analysts.

argenx's stock was trading at $378.83 at the beginning of 2023. Since then, ARGX shares have increased by 2.7% and is now trading at $389.10.
View the best growth stocks for 2023 here.

argenx saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 1,100,000 shares, an increase of 23.0% from the April 30th total of 894,500 shares. Based on an average daily volume of 243,000 shares, the short-interest ratio is currently 4.5 days.
View argenx's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, July 27th 2023.
View our ARGX earnings forecast.

argenx SE (NASDAQ:ARGX) announced its quarterly earnings results on Thursday, May, 4th. The company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($2.34) by $1.82. The firm earned $229.76 million during the quarter, compared to the consensus estimate of $191.24 million. argenx had a negative trailing twelve-month return on equity of 35.36% and a negative net margin of 79.45%.

ETFs with the largest weight of argenx (NASDAQ:ARGX) stock in their portfolio include VanEck Biotech ETF (BBH), Loncar Cancer Immunotherapy ETF (CNCR), American CenturyFocused Dynamic Growth ETF (FDG), AdvisorShares Dorsey Wright ADR ETF (AADR), iShares Biotechnology ETF (IBB), Goldman Sachs Future Health Care Equity ETF (GDOC), Invesco Nasdaq Biotechnology ETF (IBBQ) and Invesco NASDAQ Next Gen 100 ETF (QQQJ).

Based on aggregate information from My MarketBeat watchlists, some companies that other argenx investors own include Galapagos (GLPG), Kohl's (KSS), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Neurocrine Biosciences (NBIX), Pfizer (PFE), CRISPR Therapeutics (CRSP), Fate Therapeutics (FATE), NVIDIA (NVDA) and Sarepta Therapeutics (SRPT).

(ARGX) raised $65 million in an IPO on Thursday, May 18th 2017. The company issued 3,600,000 shares at a price of $18.18 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

argenx trades on the NASDAQ under the ticker symbol "ARGX."

argenx's stock is owned by a number of retail and institutional investors. Top institutional shareholders include FMR LLC (9.40%), Price T Rowe Associates Inc. MD (6.87%), Artisan Partners Limited Partnership (5.45%), Avoro Capital Advisors LLC (2.31%), Jennison Associates LLC (2.04%) and BlackRock Inc. (1.20%).

Shares of ARGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ARGX stock can currently be purchased for approximately $389.10.

argenx (NASDAQ:ARGX) has a market capitalization of $21.67 billion and generates $445.27 million in revenue each year. The company earns $-709,590,000.00 in net income (profit) each year or ($9.29) on an earnings per share basis.

The company employs 650 workers across the globe.

argenx's mailing address is Willemstraat 5, Breda P7, 4811 AH. The official website for the company is www.argenx.com. The company can be reached via phone at (176) 303-0488 or via email at info@argenx.com.